Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Epclusa
Pharma
FDA approves oral pellet version of Gilead's Epclusa
The FDA has approved an oral pellet formulation of Gilead’s hepatitis C drug Epclusa for use in young children who cannot swallow tablets.
Nick Paul Taylor
Jun 15, 2021 8:15am
No love for Merck, BMS PD-1s on China's reimbursement list
Dec 2, 2019 11:59am
Gilead’s hep C generics now own more than 20% of market
Sep 16, 2019 11:34am
Louisiana picks Gilead to partner on 'Netflix' model for hep C drugs
Mar 27, 2019 10:45am
Despite 35 price hikes, Sanofi’s net prices fell again in 2018
Feb 21, 2019 8:12am
Gilead airs first ads for hep C brand Epclusa
Feb 4, 2019 10:22am
